



ASX RELEASE

23 March 2017

### **Final participant treated in Phase 2 hay fever trial**

#### **Key Highlights:**

- Paradigm achieves major clinical milestone with the successful treatment of last participant in Phase 2 hay fever clinical trial in Lund, Sweden;
- Phase 2 results expected by late June 2017;
- Paradigm Biopharma's Pentosan Polysulfate Sodium has the potential to be first in class as a dual treatment for both early and late stage hay fever in one nasal spray.

**Paradigm Biopharmaceuticals Ltd (ASX:PAR)** is pleased to announce that it has achieved a major clinical milestone in its ground-breaking Phase 2 (n=80) allergic rhinitis (hay fever) trial, with the successful treatment of the last clinical trial participant.

The Company also reaffirms that the trial remains on schedule and on budget, with results expected by late June 2017.

Paradigm Biopharma's Pentosan Polysulfate Sodium (PPS) product has the potential to be first in class as a dual treatment for both early and late stage hay fever in one nasal spray. The drug is unique in that it treats both stages of hay fever, unlike current treatments which only treat the early or late stages of the condition.

In the early stage, the drug inhibits the release of histamines reducing the symptom of rhinorrhea or runny nose. In the late stage, the drug also blocks the inflammatory cytokines (IL-4, IL-5 and IL-13) which drive the inflammatory response (congestion). The drug is non-steroidal and the final product will address user dissatisfaction and steroid-phobia encountered with current medicines.

“We are very pleased to be on track and on budget with this trial for what has the potential to be a groundbreaking treatment for hay fever sufferers. The completion of the trial represents a major milestone for our Company and we are looking forward to the read-out of the trial by the end of June,” said Paradigm Biopharma Director and Chief Executive Officer, Paul Rennie.

Mr. Rennie added: “Post a positive Phase 2 result, we expect there to be significant partnering interest due to the significant benefits of a single product treating both the early and late stages of the disease which is something no other drugs have been able to achieve to date. For hay fever sufferers, the convenience of a single-use medication is important but also is fact that the drug (PPS) is not a steroid-based drug.”

Paradigm aims to have results published in peer-reviewed journals later this year and looks forward to updating investors on its progress.

The Phase 2a clinical trial is a double blind, placebo controlled, cross-over allergen challenge study treating subjects with allergic rhinitis (hay fever).

It is being conducted under the leadership of Dr Lennart Greiff at Skane University Hospital who has previously conducted similar clinical trials, using the established allergen challenge clinical model for allergic rhinitis, for global pharmaceutical companies including AstraZeneca.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Paul Rennie  
Director & CEO  
Paradigm BioPharmaceuticals Ltd  
Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA  
ABN: 94 169 346 963  
Web: <http://paradigmbiopharma.com/>  
Email: [prennie@paradigmbiopharma.com](mailto:prennie@paradigmbiopharma.com)  
Mobile International: +61 437 778 300  
Mobile (Australia): 0437 778 300